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Abstract. Ahmed N, Mazya M, Nunes AP, et al. Safety
and outcomes of routine endovascular
thrombectomy in large artery occlusion recorded
in the SITS Register: An observational study. J
Intern Med 2021;
Background and objective. We aimed to evaluate the
safety and outcomes of thrombectomy in anterior
circulation acute ischaemic stroke recorded in the
SITS–International Stroke Thrombectomy Register
(SITS-ISTR) and compare them with pooled ran-
domized controlled trials (RCTs) and two national
registry studies.
Methods. We identified centres recording ≥10 consec-
utive patients in the SITS-ISTR with at least 70% of
available modified Rankin Scale (mRS) at 3 months
during 2014–2019. We defined large artery occlu-
sion as intracranial internal carotid artery, first
and second segment of middle cerebral artery and
first segment of anterior cerebral artery. Outcome
measures were functional independence (mRS
score 0-2) and death at 3 months and symptomatic
intracranial haemorrhage (SICH) per modified
SITS-MOST.
Results. Results are presented in the following order:
SITS-ISTR, RCTs, MR CLEAN Registry and German
Stroke Registry (GSR). Median age was 73, 68, 71
and 75 years; baseline NIHSS score was 16, 17, 16
and 15; prior intravenous thrombolysis was 62%,
83%, 78% and 56%; onset to reperfusion time was
289, 285, 267 and 249 min; successful recanal-
ization (mTICI score 2b or 3) was 86%, 71%, 59%
and 83%; functional independence at 3 months
was 45.5% (95% CI: 44–47), 46.0% (42–50), 38%
(35–41) and 37% (35–41), respectively; death was
19.2% (19–21), 15.3% (12.7–18.4), 29.2% (27–32)
and 28.6% (27–31); and SICH was 3.6% (3–4), 4.4%
(3.0–6.4), 5.8% (4.7–7.1) and not available.
Conclusion. Thrombectomy in routine clinical use
registered in the SITS-ISTR showed safety and
outcomes comparable to RCTs, and better
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functional outcomes and lower mortality than
previous national registry studies.
Keywords: real-world registry, stroke, thrombectomy.
Introduction
Randomized controlled trials (RCTs) have demon-
strated the benefit of thrombectomy with second-
generation devices (mainly stent retrievers) over
medical therapy alone among patients with ante-
rior circulation acute ischaemic stroke due to large
artery occlusions (LAO) [1–6]. Thrombectomy
results in a high rate of arterial recanalization
and significantly improves functional outcomes at
3 months with no increase in mortality [7, 8].
Currently, thrombectomy devices are approved by
the US Food and Drug Administration for use up to
8 h after symptom onset, and Canadian guidelines
additionally recommend thrombectomy for
selected patients up to 12 h after symptom onset
[9–11]. Recently published results of the DAWN
[12] and DEFUSE 3 [13] trials demonstrated that
thrombectomy can be effective in selected patients
up to 24 h after being last seen without acute
stroke symptoms. International guidelines recom-
mend treatment 6–16 h if within DAWN or
DEFUSE-3 criteria, and 16-24 if within DAWN
criteria [14, 15]. After the publication of first
positive trial on endovascular thrombectomy [1],
most of the trials were prematurely stopped for
ethical reasons [2–6]. Although meta-analyses of
these trials show benefit of endovascular
thrombectomy over standard medical care [7, 8],
additional data on real-world experience of
endovascular thrombectomy are desirable to verify
whether the results of RCTs hold true in routine
clinical practice. Moreover, published data are
limited on thrombectomy in routine clinical prac-
tice, in particular international data on treatment
safety and outcomes. The SITS (Safe Implementa-
tion of Treatment in Stroke)–International Stroke
Thrombectomy Registry (ISTR) has been collecting
international data on endovascular thrombectomy
in routine clinical practice since 2014.
Aim
We aimed to evaluate the safety and outcomes of
thrombectomy in patients with anterior circulation
acute ischaemic stroke with LAO as recorded in the
SITS-ISTR, compared with patients in the active
arms of RCTs [8] and two national thrombectomy
registry studies [16, 17].
Methods
Data source
We collected data from the SITS-ISTR, an ongoing
prospective academic-driven multinational registry
for centres using thrombectomy for the treatment
of acute ischaemic stroke.
Centre selection
Centres recording at least 10 consecutive patients
in the SITS-ISTR and each with at least 70% of
complete data for 3-month outcomes during the
period of 1 January 2014 to 3 September 2019
were included in the study.
Patient selection
Acute ischaemic stroke patients with CT/MRI
angiography verified anterior circulation LAO
defined as intracranial internal carotid artery
(ICA), first (M1) and second (M2) segment of the
middle cerebral artery and first segment of the
anterior cerebral artery (A1) were included in the
analysis.
HERMES data [8], MR CLEAN Registry [16] and
German Stroke Registry (GSR) [17] results were
collected from their respective publications.
Variables
Baseline and demographic characteristics includ-
ing cerebrovascular risk factors, medication at
stroke onset, stroke severity using the National
Institutes of Health Stroke Scale (NIHSS) score and
pre-stroke disability using the modified Rankin
Scale (mRS) score, site of occlusion, brain imaging
prior to treatment, type of anaesthesia, recanaliza-
tion status according to modified thrombolysis in
cerebral infarction (TICI) score, blood pressure,
NIHSS at 2, 24 h and 7 days or discharge (what-
ever comes first) following treatment, follow-up
brain imaging scans at 22–36 h after treatment
and any other extra imaging scans to assess for
haemorrhagic transformation, mRS at 3 months
were the study variables. Haemorrhagic transfor-
mation was categorized using the SITS-MOST [18]
definitions into haemorrhagic infarction (HI) type 1,
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HI2, parenchymal haemorrhage (PH) type 1, PH2,
remote PHr1 and PHr2.
Outcome parameters
Primary endpoints
For efficacy: Functional independence at 3 months
(defined as a mRS 0-2).
For safety: Symptomatic intracranial haemorrhage
(SICH) according to the modified SITS-MOST) and
mortality within 3 months. SITS-MOST [16] was
defined as ≥4-point increase in NIHSS from base-
line to 24 h or death within 24 h and PH2 or PHr2
or in the 22–36 h post-EVT imaging scans. In the
modified SITS-MOST, any subarachnoid haemor-
rhage in the 22–36 h post-thrombectomy imaging
scans was added to the definition.
Definitions of SICH varied between SITS, RCTs and
the MR CLEAN Registry. The GSR publication did
not report SICH data.
Secondary endpoints
1 SICH per ECASS II [19] defined as ≥4-point
increase in NIHSS from baseline to 7 days or
death within 7 days and any haemorrhagic
transformation categorized using the ECASS
trial definitions (HI1, HI2, PH1, PH2, PHr1 and
PHr2) in the post-EVT imaging scans.
2 Proportion of patients with excellent recovery
(mRS score 0–1) at 3 months.
3 Proportion of patients with NIHSS score 0–2 at
24 h.
4 Proportion of patients with major early neuro-
logical recovery at 24 h, defined as a reduction
in NIHSS score from baseline of at least 8 points
or reaching 0–1; and change in NIHSS score
from baseline to 24 h.
5 NIHSS score at 24 h (mean, median).
6 NIHSS score change from baseline to 24 h (mean
change, median change).
7 PH2 (blood clot occupying >30% of the infarcted
territory with substantial mass effect) within 22–
36 h or any extra imaging scans.
8 All-cause death at 3 months.
9 Recanalization of the occluded artery, defined as
at least TICI 2b flow in the treated territory after
procedure.
10 Time from stroke onset to recanalization to any
TICI.
Statistical analysis
Descriptive statistics for the baseline and demo-
graphic data are presented for the SITS-ISTR
cohort and published results of the pooled active
arms of the RCTs. Unknown or missing values were
excluded from the denominator when calculating
proportions in the SITS-ISTR. Proportions and 95%
confidence intervals for outcomes were calculated
and presented for comparison with the correspond-
ing proportion in the active arm of the pooled RCTs
and two national registries. The 95% confidence
intervals for proportions were calculated using the
Wilson procedure with a correction for continuity
according to methods described by Newcombe [20].
Outcomes were compared between patients treated
with thrombectomy according to stroke symptom
onset to arterial puncture time.
Sensitivity analyses were undertaken on data from
centres that had lower rates of complete data for 3-
month outcome (70–94%) compared with centres
that had a high rate (≥95%) of 3-month complete
data.
All analyses were performed using STATISTICA
13.1 and SPSS v.25.
Ethics
Ethical approval or patient consent for participa-
tion in the SITS-ISTR differed among participating
countries. Ethical approval and patient consent
were obtained in countries that required this, while
other countries approved the register for conduct
as an anonymized audit. The SITS Register was
approved by the Ethics Committee in Stockholm,
Sweden.
Results
Figure 1 shows the study flow chart. In total, 6350
patients from 16 countries and 42 centres were
included in the final analysis. The rate of mRS
availability at 3 months was 86%. Appendix S1
shows the contributing countries, centres and
centre coordinators.
Table 1 shows the baseline and demographic char-
acteristics. SITS thrombectomy patients were older
than in HERMES and the MR CLEAN Registry, but
younger than in the GSR, and more often had a
history of hypertension and diabetes mellitus
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compared with HERMES and the MR CLEAN
Registry, but less often than GSR patients. Gender
distribution, baseline stroke severity, history of
atrial fibrillation and blood glucose were similar
between the groups. SITS-ISTR patients had a
higher proportion of M2 occlusion compared with
HERMES and the MR CLEAN Registry, but a lower
proportion than in the GSR. SITS-ISTR patients
had a lower proportion of prior treatment with
intravenous thrombolysis (IVT) than HERMES and
the MR CLEAN Registry, but higher than GSR
patients. In SITS-ISTR, stroke onset to IVT initia-
tion was longer than in HERMES and the MR
CLEAN Registry. Stroke onset to reperfusion time
was comparable between SITS-ISTR and HERMES;
however, MR CLEAN had a shorter time to reper-
fusion (median 267 min).
Table 2 shows the main outcome results. The rates
of functional independence and mortality at
3 months and SICH were similar between SITS-
ISTR and HERMES. MR CLEAN Registry and GSR
patients had lower rates of functional indepen-
dence and higher rates of mortality than SITS-ISTR
and HERMES. Most of the secondary outcomes
were also similar between SITS-ISTR and
HERMES. The rate of successful recanalization
was similar between SITS-ISTR and GSR and
higher than in HERMES and the MR CLEAN
Registry. Figure 2 shows the distribution of mRS
scores at 3 months.
Of the entire study population, among 5459
patients (86%) with available 3-month mRS, 95%
(N = 5201) had available arterial puncture time.
Among these patients, arterial puncture was done
in 80% of cases within 6 h of symptom onset, 8%
within >6–8 h, 6% within >8-12 h and 6% within
>12–24 h. Table 3 shows the distribution of pri-
mary outcomes across timing strata.
In a sensitivity analysis, we examined results in
centres with at least 95% available 3-month
outcome (21 centres with 3151 patients) and
compared with centres with 70–94% available 3-
month data (21 centres with 3199 patients).
Functional independence was 44.2% vs. 47%
(P = 0.04) and mortality was 19.8% vs. 18.4%
(P = 0.19), SICH per modified SITS-MOST was
3.5% vs. 3.8% (P = 0.64), excellent outcome was
30% vs. 31.9% (P = 0.14), type 2 parenchymal
haemorrhage was 4.2% vs. 4.6%, P = 0.46, and
patients without prior IVT were 60.9% vs. 63.3%
(P = 0.04) in the centres with ≥95% 3-month data
Fig. 1 Study flow chart.
SITS Thrombectomy Registry result / N. Ahmed et al.
4 ª 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine
Journal of Internal Medicine
650 © 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine
Journal of Internal Medicine, 2021, 290; 646–654
compared with centres with 70–94% available
3-month data.
Discussion
In this 5-year observational, retrospective study of
a large, multinational cohort of anterior circulation
AIS patients with intracranial LAO treated with
thrombectomy in routine clinical practice, we
found that the treatment outcomes are comparable
with the active arms of the HERMES and national
registries. SICH rates, neurological improvement
within 24 h and functional independence at
3 months showed similar results between SITS
thrombectomy-treated patients and HERMES.
However, we observed a higher point estimate for
death within 3 months in the SITS thrombectomy
patients compared with the HERMES data. This
may be partly explained by the older age (median
difference 5 years) in SITS thrombectomy patients
compared with patients in the RCTs. We did not
have access to individual patient data from the
HERMES and therefore were unable to perform
formal statistical testing and multivariate analysis
to adjust for baseline differences between SITS-
ISTR and HERMES data. For the main outcome
results, we calculated 95% confidence intervals
(CI). Although there are some differences in point
estimates, the 95% CIs overlap for primary and
most of the secondary outcome parameters, indi-
cating that results are similar.
When comparing with the MR CLEAN Registry [16]
and GSR [17], we observed a higher frequency of
Table 1 Baseline and demographic characteristics of patients in the SITS-ISTR, patients in active arms of pooled RCTs and
two national registries
Characteristic Median
(IQR)/% (N) SITS-ISTR HERMES Data MR CLEAN Registry
German Stroke
Registry (GSR)
Age (years) 73 (63–80) 68 (57–77) 71 (60–80) 75 (64–82)
Women 50.5% (3209/6350) 48% 46.7% (694) 50.4% (1328)
Hypertension 68% (4273/6315) 56% 50.7% (745/1488) 75.7% (1976/2612)
Diabetes mellitus 19% (1220/6313) 13% 17.2% (255/1488) 21.1% (550/2612)
Atrial fibrillation 31% (1940/6308) 33% 22.3% (327/1488) 40.9% (1067/2606)
Previous stroke 11% (686/6314) – 16.8% (249/1488) –
Smoking 22% (1351/6069) 31% 22.9% (338/1488) 15.2% (349/2289)
NIHSS 16 (11–20) 17 (14–20) 16 (11–20) 15 (10–19)
Blood glucose
(mmol L1)
6.7 (5.8–8.1) 6.6 (5.9–7.8) Not available Not available
Systolic blood pressure 150 (130–166) Not available Not available Not available
Diastolic blood pressure 80 (70–90) Not available Not available Not available
Intracranial internal
carotid artery
16% (1022/6350) 21% 22% (313/1488) 26% (666/2565)
First segment of MCA
(M1)
67% (4259/6350) 69% 58% (825/1488) 53.6% (1374/2565)
Second segments of the
MCA (M2)
16.8% (1057/6350) 8% 12.3% (175/1488) 20.1% (516/2565)
Other/ACA 0.2% (12/6350) 2% 1.9% (27/1488) 3.4% (86/2565)
Treatment with IV tPA 62.1% (61–63%)
(3944/6350)
83% 78% (1161/1488) 55.8% (1457/2610)
Onset to IV tPA 120 (90–174) 100 (75–133) 80 (62–120) –
Onset to reperfusion 289 (208–405) 285 (210–362) 267 (217–331) 249 (191–325)
NIHSS, National Institute of Health Stroke Scale; MCA, middle cerebral artery; ACA, anterior cerebral artery; IV tPA,
intravenous tissue plasminogen activator.
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functional independence at 3 months in the SITS-
ISTR and lower rate of death within 3 months and
SICH (3% vs. 5.8%, P < 0.001, not available for
GSR). The better outcomes in the SITS-ISTR than
in the MR CLEAN Registry and GSR could partly
be explained by higher proportions of patients
with ICA occlusion in the two latter (28% and 26%
vs. 17% in the SITS-ISTR [21]. Moreover, the SITS-
ISTR patients had higher proportions of success-
ful recanalization (TICI2b/3), at 86%, compared
with HERMES at 71% and the MR CLEAN Registry
at 59%. Recanalization is one of the most impor-
tant predictors for 3-month functional outcome.
Meanwhile, the MR CLEAN Registry employs cen-
tral independent adjudication for recanalization
grade, which may give a more conservative esti-
mate [16].
When comparing with HERMES, some known
prognostic factors for long-term outcome were
unfavourable in the SITS-ISTR population: higher
age, higher frequency of hypertension and diabetes
mellitus, and longer onset to IVT treatment time
than in the HERMES data. On the other hand,
some prognostic factors were favourable for the
SITS-ISTR population, such as a lower proportion
of smoking history and higher proportion of distal
(M2) occlusion. However, stroke severity as mea-
sured by NIHSS score, history of atrial fibrillation
and blood glucose were similar between the SITS
thrombectomy and HERMES. SITS-ISTR and GSR
patients were older and had a higher frequency of
cardiovascular risk factors compared with the MR
CLEAN Registry. Patients in the SITS-ISTR also
had a higher proportion of M2 occlusions
Table 2 Main outcomes in the SITS-ISTR compared with pooled RCTs and two national registries
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type 2 at 24 h
4.4% (3.9–4.9) 263/
6003
5.1% (3.6–7.2) – 13.2%d 349/
2637
Successful recanalization
(mTICI score 2b or 3)
85.7% (85–87) 4573/
5339
71% (66.6–74.2) 58.7% 743/1266 83% 1857/2236








or NIHSS 0-1 at 24 h
44.1% (43–45) 2351/
5336
50.2% (46.1–54.2) – –
NIHSS change 0–24 h
Mean (SD)/Median (IQR)
5.2 (7.7) 5 (11 to
0)
6.4 (8.2)
7 (12 to 1)
– –
aDefinitions varied between RCTs in the HERMES.
bMR CLEAN Registry used the Heidelberg criteria.
cRCTs definition did not include petechial haemorrhagic infarction.
dAny haemorrhage at 24-h imaging.
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compared with the MR CLEAN Registry, which may
contribute to better outcome in the former.
Parenchymal hematoma type 2 (PH2) and SICH
rates were comparable between the SITS-ISTR and
HERMES. In the pooled RCTs, the definition of
SICH varied across the individual trials. Our pri-
mary definition of SICH was per the modified SITS-
MOST definition [18]. We also presented additional
SICH per the ECASS-II definition for the SITS-ISTR
[19]. As expected, the point estimate of SICH per
ECASS-II rate was higher in the SITS-ISTR than
SICH defined in the pooled RCT; however, the
ECASS-II definition includes petechial haemor-
rhagic infarction, in which the RCTs did not
include in their SICH definition. For both SICH
definitions, our observed 95% CI overlaps with the
SICH in the HERMES data. These divergences in
definitions used for SICH render the results diffi-
cult to compare.
In the SITS-ISTR population, a higher proportion
received thrombectomy without prior IVT, com-
pared with HERMES and the MR CLEAN Registry,
but slightly lower than in the GSR. Thus, both SITS
and GSR cohorts included more patients with IVT
contraindications, such as unknown onset time or
time since last seen well >4.5 h.
In SITS-ISTR, arterial puncture was done within
6 h after stroke onset in the majority of cases
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Fig. 2 Outcomes per the modified Rankin Scale (mRS) at three-month follow-up in the SITS-ISTR, HERMES data, MR
CLEAN Registry and German Stroke Registry (GSR) cohorts.









mRS 3m 0-2 46% 43% 48% 41% 0.17
SICH per modified
SITS-MOST
3.9% 3.7% 4.8% 3.5% 0.83
Death within 3m 20% 17% 20% 19% 0.37
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difference in outcomes between the groups accord-
ing to onset to puncture time. Time remains an
important factor for good functional outcome.
We did not observe any significant differences in
functional outcomes and mortality at 3 months
between centres categorized by their availability of
3-month data. Although some centres did not
achieve >70% completeness, the overall 3-month
data availability is 86% for the study population,
which is acceptable for a registry-based observa-
tional study.
Important limitations of our study should be con-
sidered. These include the observational design.
We used published results from the HERMES
collaboration for comparison due to lacking access
to individual patient data. Another limitation is the
missing data at various time points. Interpretation
of our results requires caution, due to likely
influence of case mix. Lack of central adjudication
of imaging data is another limitation of our study.
Selection bias for centres with lower proportion of
3-month available data is an important issue and a
potential limitation of our study, as is the 14% rate
of missing outcome data within the retained pop-
ulation. Other limitations include absence of on-
site monitoring and source data verification, and
the unblinded assessment of outcomes, which may
be susceptible to investigator bias.
The strength of our study is the large number of
patients from an international registry, with data
contributed by 42 centres in 16 countries over
more than 5 years of real-life clinical practice.
In conclusion, safety and outcome after thrombec-
tomy in routine clinical use for anterior circulation
ischaemic stroke are similar to that in randomized
clinical trials. SITS-ISTR patients had a higher
functional outcome and lower mortality than two
studies based on large national stroke registries.
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